Ontario is known for academic excellence and high impact science, but historically has not been considered a hub for the biotech industry. Yet the Greater Toronto Area has emerged as one of the highest growth tech centres in North America and an emerging global innovation hub. Within biotechnology, the Ontario Institute for Cancer Research (OICR) and FACIT are leading the innovation pathway for oncology, and signify a province undergoing rapid transformation. OICR has a collaboration reach of over 1800 cancer scientists and clinicians, and is fully integrated with FACIT, a unique commercialization venture group. These partners have strategically laid the foundation for a collaborative innovation commercialization pathway, and global partners have taken notice. This was recently showcased through Ontario’s ‘discovered & developed’ WDR5 therapeutic program, which was the focus of the largest biotech asset transaction in the history of academia/NFPs.
Session ID: 546532